Interleukin 38 reduces antigen-presentation capacity and antibody production after vaccination.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE
    • Publication Information:
      Publication: Amsterdam, The Netherlands : Elsevier Science
      Original Publication: [Guildford, Surrey, UK] : Butterworths, [c1983-
    • Subject Terms:
      Leukocytes, Mononuclear*/immunology ; Antigen Presentation*/immunology ; Antibody Formation*/immunology ; Phagocytosis* ; Interleukins*/immunology; Humans ; Female ; Adult ; Young Adult ; Middle Aged ; Adolescent ; Vaccination ; BCG Vaccine/immunology ; BCG Vaccine/administration & dosage ; Diphtheria-Tetanus-acellular Pertussis Vaccines/immunology ; Dendritic Cells/immunology ; Cytokines/immunology
    • Abstract:
      The mechanisms that underpin low vaccine responses, which can lead to inadequate protection against infection, are still partially unclear. Interleukin (IL)-38 is a member of the IL-1 family, expressed by B cells among others, that regulates inflammatory responses. A recent study shows that IL-38 suppresses plasma cell generation and antibody production upon immune activation. We hypothesis that IL-38 affects antigen-presentation capacity of innate immune cells, effecting antibody production. Here, we investigated the effect of recombinant human IL-38 on human peripheral blood mononuclear cells and myeloid-derived DCs regarding cytokine production, phagocytosis, and expression of MCH II and co-stimulatory proteins in vitro, and further relate circulating plasma IL-38 concentrations to antibody responses in a cohort of 75 females aged 18-48 vaccinated with BCG and Tdap-IPV. To this end, we found that IL-38 decreased the expression of HLA-DR, HLA-DM, and CD83 on PBMCs, and CD40 and CD86 on MDDCs. IL-38 further impaired phagocytosis capacity of monocytes. Lastly, antibody production against diphtheria toxoids up to eight months post-vaccination was negatively associated with IL-38 plasma concentrations. These data suggest that IL-38 could dampen the effectiveness of antigen-presentation and phagocytosis, and could therefore modulate the immunogenicity of some vaccine types.
      Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
      (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
    • Contributed Indexing:
      Keywords: Antibodies; Interleukin-38; Non-responders; Vaccination
    • Accession Number:
      0 (Interleukins)
      0 (IL-38 protein, human)
      0 (BCG Vaccine)
      0 (Diphtheria-Tetanus-acellular Pertussis Vaccines)
      0 (Cytokines)
    • Publication Date:
      Date Created: 20241001 Date Completed: 20241213 Latest Revision: 20241213
    • Publication Date:
      20241213
    • Accession Number:
      10.1016/j.vaccine.2024.126396
    • Accession Number:
      39353267